Viking Therapeutics to present new data on NAFLD candidate at liver congress
Viking Therapeutics announced that data from the company's 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease, or NAFLD, and elevated low-density lipoprotein cholesterol, will be presented at the International Liver Congress 2019 being held April 10-14 in Vienna. The Phase 2 study achieved both its primary and secondary endpoints, and demonstrated an "encouraging" safety and tolerability profile for VK2089, Viking's novel liver-selective thyroid receptor beta agonist. The presentation will include new data from the trial's low-dose 5 mg cohort treatment arm, which demonstrated statistically significant reductions in liver fat content relative to placebo, as well as statistically significant response rates, defined by the proportion of patients experiencing at least a 30% or 50% relative reduction in liver fat, compared with placebo. VK2809 was well tolerated when dosed at 5 mg daily, and no serious adverse events were reported among patients receiving either VK2809 or placebo.